Addressing the unmet need of life-threatening anemia with hemoglobin-based oxygen carriers

Transfusion

Volumn 57, Issue 1, 2017, Pages 207-214

  Weiskopf, Richard B ^a   Beliaev, Andrei M ^b   Shander, Aryeh ^c   Guinn, Nicole R ^d,e   Cap, Andrew P ^f   Ness, Paul M ^g   Silverman, Toby A ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; PLASMA SUBSTITUTE; POLYMERIZED HEMOGLOBIN; UNCLASSIFIED DRUG; OXYGEN;

ANEMIA; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN DETERMINATION; HOSPITAL PATIENT; HUMAN; MORTALITY; NONHUMAN; NOTE; ORTHOPEDIC SURGERY; SURGICAL PATIENT; SURVIVAL; ERYTHROCYTE; METABOLISM;

ANEMIA; ERYTHROCYTES; HEMOGLOBINS; HUMANS; OXYGEN;

EID: 85003936018     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13923     Document Type: Note

References (54)

1. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998;279:217-21.
2. Weiskopf RB, Toy P, Hopf HW, et al. Acute isovolemic anemia impairs central processing as determined by P300 latency. Clin Neurophysiol 2005;116:1028-32.
3. Goodin DS. Event-related potentials. In: Aminoff MJ, editor. Electrodiagnosis in clinical neurology, 4th ed. San Francisco: Churchill Livingstone; 1999. p. 569-85.
4. Goodin DS, Aminoff MJ. Electrophysiological differences between subtypes of dementia. Brain 1986;109:1103-13.
5. Goodin DS, Aminoff MJ. Electrophysiological differences between demented and nondemented patients with Parkinson's disease. Ann Neurol 1987;21:90-4.
6. Polich J. P300 and clinical patients. Clin Electroenceph 2002;33:vi.
7. Polich J, Herbst KL. P300 as a clinical assay: rationale, evaluation, and findings. Int J Psychophysiol 2000;38:3-19.
8. Weiskopf RB, Kramer JH, Viele M, et al. Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology 2000;92:1646-52.
9. Weiskopf RB, Feiner J, Hopf HW, et al. Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia. Anesthesiology 2002;96:871-7.
10. Weiskopf RB, Silverman TA. Balancing potential risks and benefits of hemoglobin-based oxygen carriers. Transfusion 2013;53:2327-33.
11. Docherty AB, O'Donnell R, Brunskill S, et al. Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ 2016;352:i1351.
12. Holst LB, Petersen MW, Haase N, et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ 2015;350:h1354.
13. Fominskiy E, Putzu A, Monaco F, et al. Liberal transfusion strategy improves survival in perioperative but not in critically ill patients. A meta-analysis of randomised trials. Br J Anaesth 2015;115:511-9.
14. Hovaguimian F, Myles PS. Restrictive versus liberal transfusion strategy in the perioperative and acute care settings: a context-specific systematic review and meta-analysis of randomized controlled trials. Anesthesiology 2016;125:46-61.
15. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365:2453-62.
16. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21.
17. Carson JL, Noveck H, Berlin JA, et al. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002;42:812-8.
18. Shander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion 2014;54:2688-95.
19. Beliaev AM, Marshall RJ, Gordon M, et al. Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia. Vox Sang 2012;103:18-24.
20. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008;64:1484-97.
21. Mackenzie CF, Moon-Massat PF, Shander A, et al. When blood is not an option: factors affecting survival after use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg 2010;110:685-93.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Haldane JS. A Lecture on the symptoms, causes, and prevention of anoxaemia (insufficient supply of oxygen to the tissues), and the value of oxygen in its treatment. Br Med J 1919;2:65-71.
24. Adams RP, Dieleman LA, Cain SM. A critical value for O2 transport in the rat. J Appl Physiol 1982;53:660-4.
25. Cain SM. Appearance of excess lactate in anesthetized dogs during anemic and hypoxic hypoxia. Am J Physiol 1965;209:604-10.
26. Levy P, Kim S, Eckel P, et al. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol 1993;265:H340-9.
27. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17.
28. Lieberman JA, Weiskopf RB, Kelley SD, et al. Critical oxygen delivery in conscious humans is less than 7.3 ml O2 x kg(−1) x min(−1). Anesthesiology 2000;92:407-13.
29. Tobian AA, Ness PM, Noveck H, et al. Time course and etiology of death in patients with severe anemia. Transfusion 2009;49:1395-9.
30. Karkouti K, Djaiani G, Borger MA, et al. Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg 2005;80:1381-7.
31. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. Anesthesiology 1998;88:7-17.
32. Mangano DT, Wong MG, London MJ, et al. Perioperative myocardial ischemia in patients undergoing noncardiac surgery-II: incidence and severity during the 1st week after surgery. The Study of Perioperative Ischemia (SPI) Research Group. J Am Coll Cardiol 1991;17:851-7.
33. Conover C, Linberg R, Lejeune L, et al. Evaluation of the oxygen delivery ability of PEG-hemoglobin in Sprague-Dawley rats during hemodilution. Artif Cells Blood Substit Immobil Biotechnol 1998;26:199-212.
34. Reynolds PS, Barbee RW, Skaflen MD, et al. Low-volume resuscitation cocktail extends survival after severe hemorrhagic shock. Shock 2007;28:45-52.
35. Young MA, Lohman J, Malavalli A, et al. Hemospan improves outcome in a model of perioperative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch. J Cardiothorac Vasc Anesth 2009;23:339-47.
36. Young MA, Riddez L, Kjellstrom BT, et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med 2005;33:1794-804.
37. Moore EE, Moore FA, Fabian TC, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg 2009;208:1-13.
38. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999;282:1857-64.
39. Te Lintel Hekkert M, Dube GP, Regar E, et al. Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs. Am J Physiol Heart Circ Physiol 2010;298:H1103-13.
40. Meliga E, Vranckx P, Regar E, et al. Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic results. EuroIntervention 2008;4:99-107.
41. Serruys PW, Vranckx P, Slagboom T, et al. Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. EuroIntervention 2008;3:600-9.
42. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265-9.
43. Ignarro LJ, Byrns RE, Buga GM, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866-79.
44. Carlsen E, Comroe JH Jr. The rate of uptake of carbon monoxide and of nitric oxide by normal human erythrocytes and experimentally produced spherocytes. J Gen Physiol 1958;42:83-107.
45. Gibson QH, Roughton FJ. The reactions of sheep haemoglobin with nitric acid oxide. J Physiol 1955;128:69-70P.
46. Hartman JC, Argoudelis G, Doherty D, et al. Reduced nitric oxide reactivity of a new recombinant human hemoglobin attenuates gastric dysmotility. Eur J Pharmacol 1998;363:175-8.
47. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998;16:672-6.
48. Wellum GR, Irvine TW Jr, Zervas NT. Dose responses of cerebral arteries of the dog, rabbit, and man to human hemoglobin in vitro. J Neurosurg 1980;53:486-90.
49. Viele M, Weiskopf R, Fisher D. Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology 1997;86:848-58.
50. Silverman TA, Weiskopf RB; Planning Committee and the Speakers. Hemoglobin-based oxygen carriers: current status and future directions. Anesthesiology 2009;111:946-63.
51. Silverman TA, Weiskopf RB. Hemoglobin based oxygen carriers: current status and future directions. Transfusion 2009;49:2495-515.
52. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 1994;34:396-401.
53. Bacchetti P, McCulloch C, Segal MR. Being ‘underpowered’ does not make a study unethical. Stat Med 2012;31:4138-9; author reply 4140-1.
54. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-62.